SCHEMBL6296499

SCHEMBL6296499

CC(C)C(=O)C=Cc1ccccc1F

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.58
RAB9A P51151 4/20 0.58
MAOB P27338 2/20 0.53
NFE2L2 Q16236 4/20 0.52
CYP1B1 Q16678 2/20 0.50
CYP1A2 P05177 2/20 0.50
CYP2D6 P10635 1/20 0.50
MAPT P10636 3/20 0.49
RECQL P46063 2/20 0.49
NPC1 O15118 1/20 0.48
CYP1A1 P04798 1/20 0.46
LMNA P02545 3/20 0.45
MEN1 O00255 1/20 0.45
JAK2 O60674 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2C19 P33261 1/20 0.45
HTT P42858 1/20 0.45
KMT2A Q03164 1/20 0.45
ALDH1A1 P00352 2/20 0.44
MAPK1 P28482 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6296497 1.00 SMN1; SMN2 (0.58) SMN1; SMN2RAB9AMAOBNFE2L2CYP1B1
SCHEMBL6369895 0.86 PTGS2 (0.54) SMN1; SMN2RAB9AMAOBCYP1B1CYP1A2
SCHEMBL6298509 0.85 RAB9A (0.45) SMN1; SMN2RAB9AMAOBCYP1B1CYP1A2
SCHEMBL6298508 0.85 RAB9A (0.45) SMN1; SMN2RAB9AMAOBCYP1B1CYP1A2
SCHEMBL25142238 0.80 MAPT (0.65) RAB9ANFE2L2CYP1B1MAPTNPC1
SCHEMBL6297849 0.80 ABCG2 (0.51) SMN1; SMN2RAB9AMAOBNFE2L2MAPT
SCHEMBL6297846 0.80 ABCG2 (0.51) SMN1; SMN2RAB9AMAOBNFE2L2MAPT
SCHEMBL1781200 0.79 MAPT (0.63) SMN1; SMN2RAB9AMAOBNFE2L2CYP1B1
SCHEMBL1781201 0.79 MAPT (0.63) SMN1; SMN2RAB9AMAOBNFE2L2CYP1B1
SCHEMBL31464870 0.79 MAPT (0.63) SMN1; SMN2RAB9AMAOBNFE2L2CYP1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050075390-A1 HIV protease inhibitors AGOURON PHARMACEUTICALS, INC. 2005-04-07 US disclosed
US-6852711-B2 Novel dihydropyrones with tethered heterocycles having improved pharmacologic properties which potently inhibit the HIV aspartyl protease blocking HIV infectivity. The dihydropyrones are useful in the development of therapies for AGOURON PHARMACEUTICALS, INC. (US) 2005-02-08 US disclosed
US-20040106606-A1 HIV protease inhibitors BOYER FREDERICK EARL (US) 2004-06-03 US disclosed
US-6528510-B1 Dihydropyrones with tethered heterocycles; 3-(2-tert-Butyl-4-hydroxymethyl-5-methyl-phenylsulfanyl)-4-hydroxy-6 -isopropyl-6-(2-pyridin-4-yl-ethyl)-5,6-dihydro-pyran - 2-one; WARNER-LAMBERT COMPANY 2003-03-04 US disclosed
EP-1112269-A2 HIV PROTEASE INHIBITORS WARNER-LAMBERT COMPANY (US) 2001-07-04 EP disclosed
WO-2000015634-A2 HIV PROTEASE INHIBITORS WARNER-LAMBERT COMPANY (US) 2000-03-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040106606-A1 HIV protease inhibitors DNPEP, PREP, PEPD SMN1; SMN2 4359/4885RAB9A 3077/4885MAOB 2137/4885
US-20050075390-A1 HIV protease inhibitors DNPEP, PREP, PEPD SMN1; SMN2 4356/4885RAB9A 3024/4885MAOB 2303/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.